Dr Louise Makin
Chief Executive Officer

Louise Makin joined BTG as Chief Executive Officer in October 2004. From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998. She joined Premier Foods plc as a Non-Executive Director in October 2006. Louise has an MBA, and holds an MA in Natural Sciences and a PhD in Metallurgy from the University of Cambridge.

Christine Soden
Chief Financial Officer

Christine Soden became Chief Financial Officer and Company Secretary of BTG in July 2005. Before joining BTG she was Chief Financial Officer of Oxagen Limited, a privately owned drug discovery company, where she was responsible for the finance, IT, legal and operations functions. From 1996 until 1999, Christine was Finance Director of Chiroscience Group plc then Chief Financial Officer of Celltech Chiroscience plc following the merger of the two companies. Prior to this, Christine spent over four years as Group Financial Controller and Head of Tax and Treasury at Medeva plc. Christine has a BSc in mathematics from Durham and is a qualified Chartered Accountant.

Dr Steven Myint
Chief Medical Officer

Steven Myint graduated in medicine in 1980.  His career has spanned NHS, academia and industry, covering teaching, research and management.  His experience has included some time at the University of Leicester as Professor & Head of Microbiology, at SmithKline Beecham Pharmaceuticals as Medical Director, and at GSK as Group Medical Director.  After a period of voluntary work following the tsunami, Steven spent 18 months as the Dean and Professor of Medicine of the University of Surrey Medical School and joined BTG in February 2007 as Chief Medical Officer.

Dr Russell Hagan
Head of Research & Development

Russell Hagan joined BTG in 2002 and heads its research and development team. Russell has 25 years of pharmaceutical industry experience in a variety of roles spanning the value chain from new target discovery to Phase IV marketing. A neuropharmacologist by training he has led numerous drug discovery and development programmes in a number of therapeutic areas including schizophrenia, epilepsy and sleep disorders. He gained experience in pharmaceutical commercialisation strategies and business development in Glaxo Wellcome’s Neurology and Psychiatry Commercial Development team in North Carolina, USA.  Most recently he was Director of Strategy for one of GlaxoSmithKline’s Centres of Excellence in Drug Discovery (CEDD) based in Italy.

Dr Janet Rush
Head of Medical & Regulatory Affairs, US

Janet Rush joined BTG in 2002 as head of US medical and regulatory affairs, initially responsible for Varisolve® and subsequently for other BTG projects also.  She has 25 years of experience in pharmaceutical clinical research and regulatory affairs spanning Phases I-IV.  Prior to joining BTG, she was Worldwide VP Cardiovascular Clinical Research at Aventis (8 years) and spent 12 years at Merck (Executive Director US Clinical Development and Senior Director Cardiovascular Clinical Research).  In these positions Janet was responsible for worldwide approvals and market launches in US and Europe of five new drugs and 11 major efficacy supplements for new indications. Janet obtained her medical degree from Ohio State University and medical residency from Boston University Hospital.  She is Board Certified in Internal Medicine and a Certified Physician Investigator.

Dr Paul McCubbin
Head of Business Development

Paul McCubbin joined BTG in 2001, working initially in the Ventures unit and becoming head of that team in 2004. Since then, his responsibilities have grown to include management of the medical technologies portfolio and more recently heading up the business development group. Prior to joining BTG, Paul was the finance director of a private equity-backed healthcare company. Previously, he worked in the life sciences group at Ernst & Young. Paul is a chartered accountant who spent several years specialising in corporate recovery and turnaround assignments. He gained his degree and doctorate in biological sciences from the University of Oxford and worked as a post-doctoral researcher at Manchester University.